Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.

ABSTRACT:

Background

Dolutegravir (DTG) has recently been recommended as a preferred first-line regimen for the treatment of new and treatment-experienced HIV-infected patients. However, potential drug interactions between DTG and rifampicin remain a clinical and public health concern.

Methods

We analyzed HIV and Tuberculosis (TB) treatment outcomes of HIV-infected patients concomitantly receiving rifampicin- and DTG-based regimens under programmatic conditions in Botswana. The outcomes of interest were successful TB treatment and viral load suppression. We used multivariable logistic models to determine predictors for each outcome of interest.

Results

A total of 1225 patients were included in the analysis to evaluate predictors of successful TB outcome. Among patients on DTG a

SUBMITTER: Modongo C 

PROVIDER: S-EPMC7794061 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature